GSK poaches new drug development chief Chris Corsico from Boehringer, dividing R&D into two groups
GlaxoSmithKline is continuing its makeover in the executive team that runs its R&D group.
The pharma giant tells me that Chris Corsico, who had been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
